OncoSec Medical (LTS:0KC7) Short Interest


LTS:0KC7 OncoSec Medical Inc LTS:0KC7
40 GF Score
Price $143.00
View Full Analysis

What is OncoSec Medical Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LTS:0KC7 vs NOVNQ, USRM, VRTX: Short Interest Comparison

For the Biotechnology subindustry, OncoSec Medical's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoSec Medical Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoSec Medical's Short Interest distribution charts can be found below:

* The bar in red indicates where OncoSec Medical's Short Interest falls into.


LTS:0KC7
40GF Score
OncoSec Medical Inc LTS:0KC7
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoSec Medical Business Description

Address 820 Bear Tavern Road, Ewing, NJ, USA, 08628-1021
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.
40GF Score

Get the complete analysis for LTS:0KC7

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$143.00
Price